SEC Tracker
Get the app
GOSS · XBRL financial data

Gossamer Bio financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (GOSS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*09699*10111314*179
General and administrative99*10999*99911*199
Total operating expenses4049*42444346*47506260*6235
Operating income (loss)(40)(49)*(42)52(34)(36)*(37)(39)(49)(46)*(45)(26)
Interest income00*020(1)*0110*00
Interest expense33*3333*3333*33
Other income (expense)34*3344*3331*1(4)
Income tax expense (benefit)00*—4(1)(2)*—00(0)*——
Net income (loss)(40)(48)*(42)49(31)(33)*(37)(38)(48)(47)*(47)17
Earnings per share, basic USD per share(0.21)—(0.19)0.22(0.14)(0.15)*(0.16)(0.17)(0.21)(0.20)*(0.20)0.05
Earnings per share, diluted USD per share(0.21)—(0.19)0.22(0.14)(0.15)*(0.16)(0.17)(0.21)(0.20)*(0.20)(0.08)
Weighted average shares, basic millions of shares193—226226226227*227227228232*234320
Weighted average shares, diluted millions of shares193—226239226214*227227228232*234329

Balance sheet

CSV

Fiscal quarters (GOSS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents83323987284629269384141
Marketable securities246264206268299248229187171995816
Marketable securities, non-current——————000000
Accounts receivable—0—4757891296
Prepaid and other current assets131011131110111515181610
Total current assets34130725537134431027523620416812573
Property and equipment, net221100000000
Right-of-use asset432265554444
Total assets34831225937335131528124120917212977
Accounts payable1631323216116
Accrued liabilities172715161715121319162018
Current portion of long-term debt121210000——————
Total current liabilities4252364551454854626357138
Long-term debt410000——————
Lease liability, non-current100054444333
Total liabilities243249233292297286287287291295290171
Accumulated deficit(1,164)(1,212)(1,254)(1,205)(1,236)(1,269)(1,305)(1,343)(1,392)(1,439)(1,486)(1,469)
Total stockholders' equity1056327825429(6)(46)(82)(123)(161)(94)
Total liabilities and equity34831225937335131528124120917212977
Common shares outstanding (cover page) millions of shares225226226226227227227227231235235489

Cash flows

CSV

Fiscal quarters (GOSS's year ends in late December)

In millions of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(40)(48)*(42)49(31)(33)*(37)(38)(48)(47)*(47)17
Stock-based compensation6*6*65*5*5*23*3*3*62*
Depreciation and amortization00*0000*00*0*0*0—
Net cash from operating activities(34)*(33)*(52)116*(32)*(35)*(40)(47)*(36)*(48)*(39)(39)*
Purchases of property and equipment0*0*00*0*0*00*0*0*00*
Net cash from investing activities(118)*(14)*62(59)*(27)*53*2244*17*73*4243*
Repayments of long-term debt3*3*310*0*0*00*0*0*——
Net cash from financing activities198*(3)*(3)(9)*0*0*10*2*4*1(3)*
Net change in cash46*(51)*748*(58)*18*(17)(3)*(17)*29*30*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingRunwayQuarter
Gossamer Bio419.2(39)*488.8M1.4 quarters 10-QJun 30, 2026
Tonix Pharmaceuticals Holding17614(42)*17.2M4.2 quarters 10-QJun 30, 2026
Vanda Pharmaceuticals6270(28)*60.5M1.7 quarters 10-QSep 30, 2026
Abeona Therapeutics5611(17)*57.2M8.4 quarters 10-QJun 30, 2026
Ocugen1001.5(12)*339.1M8.2 quarters 10-QJun 30, 2026
Atea Pharmaceuticals77not reported(37)*80.2M5.9 quarters 10-QJun 30, 2026
Verastem13640(44)*90.6M3.1 quarters 10-QJun 30, 2026
Standard Biotools26719(6.2)*394.8M21.6 quarters 10-QSep 30, 2026
Corvus Pharmaceuticals19not reported(15)*84.1M14.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.